TIM-3抗体および低分子阻害剤の開発における最近のプロセスとがん免疫療法への応用

T-cell immunoglobulin and mucin domain 3 (TIM-3) is an immune checkpoint receptor that negatively regulates immune responses and represents a promising therapeutic target for cancer. The development of TIM-3 inhibitors has attracted widespread research interests. In this review, we comprehensively analyze the advancements of TIM-3 inhibitors, including monoclonal antibodies and small-molecule drugs. Specifically, the clinical progress of monoclonal antibodies is discussed, while the preclinical development of small-molecule inhibitors is detailed, focusing on lead compound discovery, structural optimization and biological activities. Moreover, we discuss the potential opportunities and challenges for developing TIM-3 inhibitors. It is hoped that this review will contribute to the development of TIM-3 inhibitors.